hVIVO plc Stock price

Equities

VENN

GB00B9275X97

Biotechnology & Medical Research

Delayed London S.E. 08:35:56 2024-03-28 am EDT 5-day change 1st Jan Change
29.07 GBX +0.57% Intraday chart for hVIVO plc -0.12% +22.38%
Sales 2023 * 66.78M 72.07M Sales 2024 * 73.55M 79.38M Capitalization 229M 248M
Net income 2023 * 10M 10.79M Net income 2024 * 10M 10.79M EV / Sales 2023 * 2.79 x
Net cash position 2023 * 43.28M 46.71M Net cash position 2024 * 50.78M 54.8M EV / Sales 2024 * 2.43 x
P/E ratio 2023 *
21.1 x
P/E ratio 2024 *
20.3 x
Employees 210
Yield 2023 *
1.38%
Yield 2024 *
0.61%
Free-Float 60.77%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.31%
1 week-1.00%
Current month+14.33%
1 month+10.38%
3 months+21.31%
6 months+44.05%
Current year+21.31%
More quotes
1 week
28.00
Extreme 28
30.00
1 month
24.50
Extreme 24.5
32.00
Current year
24.27
Extreme 24.2667
32.00
1 year
12.50
Extreme 12.5
32.00
3 years
8.68
Extreme 8.675
48.00
5 years
4.51
Extreme 4.5111
48.00
10 years
4.51
Extreme 4.5111
48.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 21-10-12
Founder 37 11-01-31
Director of Finance/CFO 61 17-06-30
Members of the board TitleAgeSince
Director/Board Member 57 22-06-07
Founder 73 18-11-30
Director/Board Member 63 20-11-23
More insiders
Date Price Change Volume
24-03-28 29.07 +0.57% 439 590
24-03-27 28.9 -1.03% 2,127,925
24-03-26 29.2 +2.46% 1,486,542
24-03-25 28.5 -0.87% 1,609,643
24-03-22 28.75 -1.20% 671,520

Delayed Quote London S.E., March 28, 2024 at 04:25 am EDT

More quotes
hVIVO plc is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services. hVIVO plc runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialized on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.3372 EUR
Average target price
0.3934 EUR
Spread / Average Target
+16.66%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock hVIVO plc - London S.E.